Dublin, Oct. 21, 2024 (GLOBE NEWSWIRE) -- The "Antineoplastic Agents - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for ...
Financial Impact of Cancer Drug Wastage and Potential Cost Savings From Mitigation Strategies Our analysis of the ASCO and ESMO value frameworks illuminates the heterogeneous benefit of new ...
Association Between Prescription Co-Payment Amount and Compliance With Adjuvant Hormonal Therapy in Women With Early-Stage Breast Cancer Randomized clinical trials (RCTs) that evaluated approved new ...
Co announces the publication of data from a preclinical study of two triple-drug combinations -- combretastatin A4 phosphate / CA4P, paclitaxel, and manumycin A, and CA4P, paclitaxel, and carboplatin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback